Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown. In this study, we found that Ibrutinib induced stronger cytotoxic effect on endothelial cells than Zanubruti...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jia, Liu, Zhuojun, Zhang, Jing, Chen, Xiaofang, Chen, Junge, Sui, Linlin, Yu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506105/
https://www.ncbi.nlm.nih.gov/pubmed/36145624
http://dx.doi.org/10.3390/pharmaceutics14091876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506105/
https://www.ncbi.nlm.nih.gov/pubmed/36145624
http://dx.doi.org/10.3390/pharmaceutics14091876

Ejemplares similares